Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the neurological disorder drugs market?

Over the past few years, the neurological disorder drugs market has experienced substantial growth. Its market size is anticipated to escalate from $84.6 billion in 2024 to $90.09 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 6.5%. The historical growth can be credited to factors such as an increase in animal testing yielding promising outcomes, a surge in therapeutic treatments, a rise in neurological disorders, government-driven initiatives, and an overall increase in spending on healthcare.

What will be the neurological disorder drugs market size in the future?

Anticipated to witness significant expansion in the coming years, the market for neurological disorder drugs is predicted to escalate to a value of $114.65 billion by 2029, advancing at a compound annual growth rate (CAGR) of 6.2%. This forecasted growth could be driven by factors such as broadening therapeutic alternatives and customized treatments, heightened attention towards disease-altering therapies, widened adoption of digital biomarkers, and a rise in cases of neurological disorders. Prominent trends for the projected timeframe encompass progress in drug formation, breakthroughs in neuroimaging, advancements in the field of genetic studies, cooperative endeavors and licensing contracts, and the introduction of regenerative medicine.

Get your neurological disorder drugs market report here!

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

What main drivers are fueling expansion in the neurological disorder drugs market?

The escalation in the incidence of neurological disorders is predicted to fuel the expansion of the neurological disorder drugs market. These disorders, which encompass conditions that affect the brain, spinal cord, and nerves due to structural, biochemical, or electrical abnormalities, lead to diverse symptoms. The global rise in neurological diseases is linked to the aging adult population and higher exposure to environmental, metabolic, and lifestyle-related risk factors. Drugs for neurological disorders are paramount in handling these complicated conditions, providing symptom relief, decelerating disease advancement, and enhancing patient prognosis over time. For example, the Australian Institute of Health and Welfare, a government agency in Australia, projected in September 2024 that the population of dementia patients in Australia would more than double from 2023 to 2058, rising from about 411,100 in 2023 to 849,300 by 2058, affecting approximately 315,500 men and 533,800 women. Consequently, the rise in the prevalence of neurological ailments is spurring the growth of the neurological disorder drugs market.

What key areas define the segmentation of the global neurological disorder drugs market?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegtments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

Who are the dominant players expanding their reach in the neurological disorder drugs market?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Novo Nordisk A/S, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

What are the key trends shaping the future of the neurological disorder drugs market?

Top corporations in the drugs market for neurological disorders are prioritizing the creation of novel Ocrelizumab drug therapies. Such groundbreaking therapies aim to not only make treatments more effective but also raise patient health results and broaden the range of treatments available to those diagnosed with multiple sclerosis. Known as a human monoclonal antibody, Ocrelizumab is employed as a medicinal drug to address multiple sclerosis, a variety of neurological disorder. In February 2024, for example, Roche Holding AG, a pharmaceutical firm hailing from Switzerland, introduced Ocrevus (Ocrelizumab) in India as a cutting-edge disease-modifying therapy (DMT) drug purposed for the treatment of multiple sclerosis. Ocrevus, the first DMT approved for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS), is backed by over a decade of data from clinical and real-world applications. This monoclonal antibody targets CD20-positive B cells, suspected contributors to the autoimmune assault on the central nervous system in multiple sclerosis (MS) cases. Ocrevus is approved for treating both RRMS and PPMS, cementing its position as the first drug sanctioned for both types of the condition. Administered intravenously approximately twice a year, Ocrevus has demonstrated effectiveness in lowering disease activity and slowing the progression of disability as seen in clinical trials.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17207

Which regions are emerging as leaders in the neurological disorder drugs market?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Myeloproliferative Disorders Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/myeloproliferative-disorders-drugs-global-market-report

Neurological Biomarkers Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurological-biomarkers-global-market-report

Bleeding Disorders Treatment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/bleeding-disorders-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: